| Website | sutrobio.com |
| @sutrobio | |
| Category | BioTech |
| Phone | 650.392.8412 |
| general@sutrobio.com | |
| Employees | |
| Founded | 2003 |
| Description | Biopharmaceuticals |
| TOTAL | $90.3M |
| FUNDING TOTAL | $90.3M |
| Series A, 1/06 SV Life Sciences | $1M |
| Venture Round, 10/07 SV Life Sciences International Biotechnology Trust | $305k |
| Series B, 12/07 SV Life Sciences Alta Partners | $21M |
| Series B, 3/09 Alta Partners SV Life Sciences | $15M |
| Series C, 11/10 Skyline Ventures Lilly Ventures Amgen Ventures SV Life Sciences Alta Partners | $36.5M |
| Series C, 5/12 Skyline Ventures Lilly Ventures Amgen Ventures SV Life Sciences Alta Partners | $16.5M |
Sutro Biopharma is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease.
Sutro is applying its technology to the development of next-generation, non-native protein structures such as antibody fragments, single-chain antibodies, and other proteins with novel scaffolds. We are also working to provide novel functionalities to our core technology with a goal of further improving the therapeutic benefit of the products we make. Sutro Biopharma, Inc. has a 24,000 sq. ft facility located in South San Francisco, California. Our pilot facility houses 15-Liter fermentors, a 200-L fermentor, and related research, development and downstream activities to support the scale-up of protein therapeutic candidates.
